US2013273071A1PendingUtilityA1

Recombinant IL-9 Antibodies And Uses Thereof

59
Assignee: MEDIMMUNE LLCPriority: Apr 11, 2003Filed: Jun 6, 2013Published: Oct 17, 2013
Est. expiryApr 11, 2023(expired)· nominal 20-yr term from priority
Inventors:Jennifer Lynne ReedHerren WuYing TangJulian DaviesJeffry D. Watkins
A61P 37/02A61P 43/00A61P 37/06A61P 37/08A61P 37/00A61P 31/04A61P 31/16A61P 25/28A61P 25/00A61P 31/12A61P 31/10A61P 35/00A61P 29/00A61P 31/00C07K 16/244A61K 39/3955C07K 2317/24A61K 45/06A61P 19/02G01N 33/6869C07K 2317/76A61P 11/00A61P 11/06C07K 2317/92A61K 2039/505C07K 16/24A61K 39/395G01N 33/53
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An IL-9 antibody comprising a variable heavy (VH) domain having an amino acid sequence of the VH domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide. 
     
     
         2 . An IL-9 antibody comprising a variable light (VL) domain having an amino acid sequence of the VL domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human 11L-9 polypeptide. 
     
     
         3 . The IL-9 antibody of  claim 1  further comprising a VL domain having an amino acid sequence of the VL domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         4 . An IL-9 antibody comprising a complementarily determining region (CDR) having an amino acid sequence of a CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide. 
     
     
         5 . The antibody of  claim 4 , wherein the antibody comprises a VH CDR having an amino acid sequence of a VH CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         6 . The IL-9 antibody of  claim 4 , wherein the antibody comprises a VL CDR having an amino acid sequence of a VL CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         7 . The IL-9 antibody of  claim 5  further comprising a VL CDR having the amino acid sequence of a VL CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         8 . The IL-9 antibody of  claim 5 , wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         9 . The IL-9 antibody of  claim 5 , wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VIA CDR2 of 4D4, 4D1 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         10 . The IL-9 antibody of  claim 5 , wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH. CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         11 . The IL-9 antibody of  claim 8 , wherein the antibody further comprises a VH, CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         12 . The IL-9 antibody of  claim 8 , wherein the antibody further comprises a CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         13 . The IL-9 antibody of  claim 9 , wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         14 . The IL-9 antibody of  claim 11 , wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1, D11, 4D4com-4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         15 . The IL-9 antibody of  claim 7 , wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         16 . The IL-9 antibody of  claim 7 , wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F19, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         17 . The IL-9 antibody of  claim 7 , wherein the antibody comprises a NTH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         18 . The IL-9 antibody of  claim 15 , wherein the antibody further comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         19 . The IL-9 antibody of  claim 15 , wherein the antibody further comprises a VIII CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         20 . The IL-9 antibody of  claim 16 , wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 41) 4 , 41) 4  H2-1 D1.1, 4D4com-4D4com-2F9, 7E3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         21 . The IL-9 antibody of  claim 8 , wherein the antibody further comprises a VIII CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 2D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         22 . The IL-9 antibody of  claim 6 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         23 . The IL-9 antibody of  claim 6 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         24 . The IL-9 antibody of  claim 6 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         25 . The IL-9 antibody of  claim 22 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         26 . The IL-9 antibody of  claim 22 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         27 . The IL-9 antibody of  claim 23 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         28 . The IL-9 antibody of  claim 25 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         29 . The IL-9 antibody of  claim 7 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         30 . The IL-9 antibody of  claim 7 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         31 . The IL-9 antibody of  claim 7 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         32 . The IL-9 antibody of  claim 29 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         33 . The IL-9 antibody of  claim 29 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22133, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         34 . The IL-9 antibody of  claim 30 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7E3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         35 . The IL-9 antibody of  claim 32 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3F15, or 7F3com-3D4. 
     
     
         36 . The IL-9 antibody of  claim 15 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         37 . The IL-9 antibody of  claim 15 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         38 . The IL-9 antibody of  claim 15 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         39 . The IL-9 antibody of  claim 36 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         40 . The IL-9 antibody of  claim 36 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, 7F3com-3D4. 
     
     
         41 . The IL-9 antibody of  claim 37 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         42 . The IL-9 antibody of  claim 39 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         43 . The IL-9 antibody of  claim 16 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 41) 4 , 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         44 . The IL-9 antibody of  claim 16 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         45 . The IL-9 antibody of  claim 16 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         46 . The IL-9 antibody of  claim 43 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7E3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         47 . The IL-9 antibody of  claim 43 , wherein the antibody further comprises VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         48 . The IL-9 antibody of  claim 44 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, 7F3com-3D4. 
     
     
         49 . The IL-9 antibody of  claim 46 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         50 . The IL-9 antibody of  claim 17 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         51 . The IL-9 antibody of  claim 17 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         52 . The IL-9 antibody of  claim 17 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 41) 4 , 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         53 . The IL-9 antibody of  claim 50 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         54 . The IL-9 antibody of  claim 50 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, 7F3com-3D4. 
     
     
         55 . The IL-9 antibody of claim. 51, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         56 . The IL-9 antibody of  claim 53 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         57 . The IL-9 antibody of  claim 15 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         58 . The IL-9 antibody of  claim 18 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         59 . The IL-9 antibody of  claim 18 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VD CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F19, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         60 . The IL-9 antibody of  claim 57 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, 7F3com-3D4. 
     
     
         61 . The IL-9 antibody of  claim 57 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         62 . The IL-9 antibody of  claim 58 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         63 . The IL-9 antibody of  claim 60 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         64 . The IL-9 antibody of  claim 19 , wherein the antibody comprises a VL CDR having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         65 . The IL-9 antibody of  claim 19 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         66 . The IL-9 antibody of  claim 19 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         67 . The IL-9 antibody of  claim 64 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         68 . The IL-9 antibody of  claim 64 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-4D4com-2F9, 7E3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         69 . The IL-9 antibody of  claim 65 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3F15, or 7F3com-3D4. 
     
     
         70 . The IL-9 antibody of  claim 67 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         71 . The IL-9 antibody of  claim 20 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 73, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         72 . The IL-9 antibody of  claim 20 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3coin-2H2, 7F3com-3H5, or 7F3coin-3D4. 
     
     
         73 . The IL-9 antibody of  claim 20 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         74 . The IL-9 antibody of  claim 71 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, 7F3com-3D4. 
     
     
         75 . The IL-9 antibody of  claim 71 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         76 . The IL-9 antibody of  claim 72 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         77 . The IL-9 antibody of  claim 74 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, 7F3com-3D4. 
     
     
         78 . The IL-9 antibody of  claim 21 , wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         79 . The IL-9 antibody of  claim 21 , wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         80 . The IL-9 antibody of  claim 21 , wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         81 . The IL-9 antibody of  claim 78 , wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         82 . The IL-9 antibody of  claim 78 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         83 . The IL-9 antibody of  claim 79 , wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         84 . The DL-9 antibody of  claim 81 , wherein the antibody further comprises VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         85 . The IL-9 antibody of  claim 1 ,  2  or  3 , wherein the antibody is a human or humanized antibody. 
     
     
         86 . The IL-9 antibody of  claim 1 ,  2  or  3 , wherein the antibody is conjugated to a detectable substance or a therapeutic agent. 
     
     
         87 . A pharmaceutical composition comprising the IL-9 antibody of  claim 1 ,  2  or  3 , and a pharmaceutically acceptable carrier. 
     
     
         88 . A method for preventing, treating, managing and/or ameliorating a disease or disorder characterized by aberrant expression and/or activity of an IL-9 polypeptide or aberrant expression and/or activity of an IL-9R, said method comprising administering to a subject in need thereof an prophylactically or therapeutically effective amount of the IL-9 antibody of  claim 1 ,  2  or  3 . 
     
     
         89 . A method for preventing, treating, managing and/or ameliorating an inflammatory disorder, autoimmune disorder, a proliferative disorder or respiratory infection or one or more symptoms thereof, said comprising administering to a subject in need thereof a dosage of a prophylactically or therapeutically effective amount of the IL-antibody of  claim 1 ,  2  or  3 . 
     
     
         90 . The method of  claim 89 , wherein the respiratory infection is caused by a virus or bacteria. 
     
     
         91 . The method of  claim 89 , wherein the virus is respiratory syncytial virus, parainfluenza virus or human metapneumovirus. 
     
     
         92 . The method of  claim 89 , wherein the inflammatory disorder is asthma, an allergy, arthritis or a disorder characterized by type 2-mediated inflammation. 
     
     
         93 . The method of  claim 89 , wherein the autoimmune disorder is rheumatoid arthritis or multiple sclerosis. 
     
     
         94 . The method of  claim 89  further comprising a dosage of a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic agents other than an IL-9 antibody. 
     
     
         95 . The method of  claim 94 , wherein at least one of the prophylactic or therapeutic agents is an anti-angiogenic agent, a TNF-α antagonist, an immunomodulatory agent, or an anti-inflammatory agent. 
     
     
         96 . The method of  claim 95 , wherein the anti-angiogenic agent is VITAXIN™. 
     
     
         97 . The method of  claim 95 , wherein the immunomodulatory agent is MEDI-507 or an anti-Epha2 antibody. 
     
     
         98 . The method of  claim 89 , wherein the antibody is administered parenterally, intranasally or orally. 
     
     
         99 . The method of  claim 89 , wherein the subject is refractory to conventional therapies for the disease or disorder. 
     
     
         100 . A method of diagnosing, proposing, or monitoring a disorder or disease characterized by aberrant expression and/or activity of an IL-9 polypeptide or aberrant expression and/or activity of an IL-9R comprising:
 (a) assaying the level of IL-9 in cells or a tissue sample of a subject using the IL-9 antibody claim of  1 ,  2  or  3 ; and   (b) comparing the assayed level of IL-9 with a control level, whereby an increase or decrease in the assayed level of IL-9 compared to the control level IL-9 is indicative of said disorder or disease.   
     
     
         101 . A kit comprising the antibody of  claim 1 ,  2  or  3  and instructions for use, in one or more containers. 
     
     
         102 . An article of manufacture comprising a packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises the IL-9 antibody of  claim 1 ,  2  or  3  and a pharmaceutically acceptable carrier. 
     
     
         103 . An IL-9 antibody, wherein said IL-9 antibody has an association rate constant or k on , rate of at least 10 5  M −1  s −1 . 
     
     
         104 . The IL-9 antibody of  claim 103 , wherein said association rate constant or k on  rate is at most 10 11  M −1  s −1 . 
     
     
         105 . An IL-9 antibody, wherein said IL-9 antibody has a dissociation rate constant or k off  rate of less than about 2×10 −4  s −1 . 
     
     
         106 . The IL-9 antibody of  claim 105 , wherein said dissociation rate constant or k off  is greater than 10 −11  s −1 . 
     
     
         107 . An IL-9 antibody, wherein said IL-9 antibody has an affinity constant (K a ) of at least 10 7  M −1 . 
     
     
         108 . The antibody of  claim 107 , wherein said affinity constant is at most 5×10 11  M −1 . 
     
     
         109 . An IL-9 antibody, wherein said IL-9 antibody has dissociation constant (K d ) of less than 10 −9  M. 
     
     
         110 . The antibody of  claim 109 , wherein said dissociation constant is greater than 6×10 − 12 M.

Join the waitlist — get patent alerts

Track US2013273071A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.